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Background: Current evidence demonstrates that positive family history and several alterations in lipid
metabolism are all important risk factors for coronary artery disease (CAD). All lipid abnormalities
themselves have genetic determinants. Thus, objective of this study was to determine whether 6 genetic
variants potentially related to altered lipid metabolism were associated with CAD and with lipid
abnormalities in an Italian population. These genetic variables were: apolipoprotein E (Apo E), Apo AI, Apo
CIII, Apo B, lipoprotein lipase (LPL) and the hepatic lipase (LIPC) genes. Furthermore, an 8 years prospective
analysis of clinical cardiovascular events was related to the various genetic markers.
Methods: 102 subjects with established coronary artery disease and 104 unrelated normal subjects were
studied. CAD Patients were followed up for 8 years, and clinical CAD outcomes (a second coronary
angioplasty (PTCA), myocardial infarction, coronary artery by-pass graft (CABG), cardiovascular deaths),
available from 60 subjects, were related to the genetic variants by multiple regression analysis. Results. Of
the six lipid loci studied (for a total of 11 polymorphisms) only the apolipoprotein E, Apo B and LIPC
polymorphisms distinguished between case and controls. However, multivariate analysis accounting for
clinical and metabolic predictors of CAD showed that only the ApoB Xba1 and ApoE4 polymorphism
associated with CAD in this Italian population. When lipid parameters were related to genotypes, the
ApoE, ApoB, and LIPC gene polymorphisms were associated to various markers of dyslipidaemia in the CAD
patients, confirming previous reports. When the occurrence of a second cardiovascular event was related
to genotypes, an independent role was observed for the LIPC gene T202T variant.
Conclusions: variation in LIPC (hepatic lipase) gene associates with clinical outcomes in Italian patients with
established CAD. Further studies on the LIPC gene in CAD patients are warranted, in particular looking at
the possible influences on clinical outcomes.
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Background
Coronary artery disease (CAD) accounts for roughly one-
half of all cardiovascular deaths and is a major cause of
morbidity and mortality. Twin studies [1,2] have demon-
strated that the concordance rates for monozygotic twins
are higher than those for dizygotic twins and familial
aggregation of CAD has long been known [1,3,4]. Current
evidence demonstrates that positive family history and
several alterations in lipid metabolism, including high
LDL (low density lipoprotein) and low HDL (high density
lipoprotein) cholesterol levels (separately as well as
jointly), high triglycerides levels, high apoB levels, high
lipoprotein (a) (Lp(a) levels, are all important risk factors
for CAD. All these lipid abnormalities themselves have
genetic determinants [5,7]. Lipoprotein levels are partly
determined by genes that code for proteins that regulate
lipoprotein synthesis, interconversions and catabolism.
Mutations in these genes may cause disturbances in one or
more of the pathways in lipoprotein metabolism resulting
in hyperlipoproteinemia, and some of these disorders
lead to premature atherosclerosis.
Marked differences in mortality rates for CAD have been
observed within Europe [8], with northern Europeans
having the highest incidence. Although environmental
factors and dietary habits may account for this difference,
a different genetic predisposition may also be involved.
Furthermore, genetic loci conferring susceptibility or pro-
tection to CAD may differ between populations. Associa-
tion study designs provide statistical power to reveal the
modest contributions of weak alleles, and evidence is
mounting that common genetic polymorphisms play a
role in complex diseases.
Thus, the associations of 6 genetic variants potentially
related to coronary artery disease (CAD) were evaluated in
univariate and multivariate models in an Italian CAD
population. These variables included: variants at the apol-
ipoprotein E (Apo E) [9], Apo AI and Apo CIII [10,11], Apo
B, lipoprotein lipase (LPL) [12], and LIPC (the gene encod-
ing hepatic lipase) genes [13].
Furthermore, a prospective analysis was performed in our
CAD population, evaluating after 8 years from recruit-
ment the occurrence of a second cardiovascular event (a
second coronary angioplasty (PTCA), myocardial infarc-
tion, coronary artery by-pass graft (CABG), cardiovascular
death) in those who had a PTCA at the time of recruitment
as sign of progression of the atherosclerotic disease, and
these events were related to the various genetic markers.
Methods
Subjects
A total number of 206 Caucasian subjects were studied
and all subjects were recruited in the Lazio region of Italy.
The 102 coronary subjects (96 men and 6 women) were
consecutively recruited among subjects undergoing coro-
nary angioplasty (60% of the sample) or presented with
clear evidence of CAD (one or more stenoses greater than
50% in at least one major coronary artery using the Sones
and Judkins scoring technique [14] after coronary cathe-
terisation and clinical symptoms of angina). All subjects
were recruited in the years 1993–1994. Subjects with con-
comitant liver or renal disease were not included. Also
excluded were those who were on lipid lowering diet and
medications.
As controls, we considered 104 age-matched unrelated
Caucasian individuals consecutively recruited from a pop-
ulation of individuals screened for CAD risk factors.
Exclusion criteria were: 1) age below 45 years, 2) the pres-
ence of type 2 diabetes, and 3) the presence of CAD. In
these subjects, CAD was excluded by use of the Rose ques-
tionnaire and ECG (Minnesota coding) [15]. In both
patients and controls a complete medical history was
obtained by questionnaire. Diagnosis of type 2 diabetes
was based on history of hypoglycaemic treatment and/or
fasting blood glucose >126 mg/dl (7 mmol/L) [16]; that
of hypertension was based on the presence of elevated
systolic (>160 mmHg) and/or diastolic (>95 mmHg)
blood pressure and/or the current use of anti-hypertensive
medications. This study complies with the Declaration of
Helsinki and was authorized by the local ethical
committee.
Lipoprotein analyses
Plasma cholesterol, triglyceride, and lipoproteins were
determined by enzymatic methods with commercially
available kits (Boehringer Mannheim and Beckman Array
Protein System, Beckamn Instruments Brea, CA.). HDL-
cholesterol was measured after precipitation of apolipo-
protein B containing lipoproteins and LDL-cholesterol
was calculated according to the Friedewald formula.
Apolipoproteins were determined by
immunonephelometry using monospecific polyclonal
antisera Greiner Biochemica (Flacht, Germany).
Genetic analyses
DNA was isolated from fresh or frozen EDTA whole blood
cells using a spin column method (Nucleon, Scotlab
U.K.). Variants at six loci previously shown to be associ-
ated with CAD [17–19] were studied, and the 11 variants
analysed were: apolipoprotein A1: Xmn1 5' to the Apo A1
gene, Msp1 in intron 3, Pst1 3' of the gene; apolipoprotein B:
Xba1; apolipoprotein CIII: Sst1 for C3175G, exon 4, apolipo-
protein E: Hha1 for e2, e3, e4; LIPC: Msp1 for Thr202Thr (C
to G); and lipoprotein lipase: Hind 111 in intron 8, Taq1
forD9N (G to A), Rsa1 for N291S (A to G), and Mnl1 for
S447X (C to G).BMC Medical Genetics 2003, 4 http://www.biomedcentral.com/1471-2350/4/8
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Primers for the polymerase chain reaction were obtained
from Genosys, Cambridge, U.K. The primer sequences
were derived from published data [17–19].
Genomic DNA (0.2–0.5 ug) was amplified with specific
primers for the 11 polymorphisms in 25 ul reaction mix-
tures according to prevously published methods. Five
microliters of digestion mixture containing the manufac-
turer's recommended restriction buffer and 5 U of the
above mentioned restriction enzymes were added to the
amplification product and incubated as described [17–
19].
Genotypes were scored by two independent investigators
who did not know whether the samples were from a case
patient or from controls.
Statistical Analysis
Categorical variables were compared by chi-square or
Fisher's exact test. Differences between continuous varia-
bles were evaluated by two-tailed Student's t-test and by
ANOVA with age correction. Logarithmic transformation
was used to normalise distributions of BMI, plasma total
and HDL cholesterol, triglycerides and Lp(a) values. Gen-
otype distributions and allele frequencies between the
study groups were compared by construction of 2 × 2 and
2 × 3 contingency tables and chi-square analysis. The
study was powered to allow detection with 80% and an
error rate of 5% for differences in allele frequencies of
11%. The relation between genotypes and concomitant
variables were evaluated by ANOVA after age-standardisa-
tion. To estimate the risk of CAD and the progression of
CAD associated with gene variants, odds ratios (i.e. odds
of CAD given the presence of the variant genotype) were
calculated by multiple regression analysis, after adjust-
ment for other modulators known to affect both condi-
tions (including sex, age, total cholesterol, HDl
cholesterol, LDL cholesterol, triglycerides, BMI). For each
odds ratio we estimated two-tailed P values and 95% con-
fidence intervals (CI). P values < 0.05 or less were taken as
statistically significant.
Results
Clinical and biochemical characteristics of study groups
Table 1 summarises the clinical features and biochemical
characteristics of the study groups. The two groups were
slightly different in age, and this is the reason why all sta-
tistics were age-corrected. As expected, the mean levels of
LDL-cholesterol, total triglycerides, Apo AI, Apo AII, Apo
CIII, Apo E and Apo B were significantly different in the
arterial disease group compared to controls. HDL-choles-
terol levels were significantly lower in CAD subjects, but
the total plasma cholesterol did not differ between the
groups.
Multiple regression analysis of known predictors of CAD
confirmed the independent role of age (OR 1.08, 95% CI
1.01–1.15, p < 0.02), sex (OR 26.4, 95% CI 4.7–146.5, p
< 0.01), LDL-cholesterol (OR 1.12, 95% CI 1.05–1.27, p
< 0.001) and HDL-cholesterol (OR 1.14, 95% CI 1.09–
1.23, p < 0.01) as risk factors for coronary artery disease in
this Italian population.
Table 1: Clinical and biochemical characteristics of study subjects
CAD subjects (n = 102) Control subjects (n = 104) p-value
Age (years) 50.1 ± 5.3 47.5 ± 3.7 <0.02
Sex (M/F) 96/6 89/15 NS
Body Mass Index (kg/m2) 26.9 ± 3.2 26.4 ± 3.7 NS
Smokers (%) 85.2% 52.5% <0.002
Hypertensive (%) 22.5 14.5 NS
Total cholesterol (mg/dl) 197.3 ± 33.7 199.8 ± 41.7 NS
HDL-cholesterol (mg/dl) 27.6 ± 8.2 38.1 ± 10.2 <0.0001
LDL-cholesterol (mg/dl) 145.6 ± 36.9 119.5 ± 32.9 <0.0001
Total triglycerides (mg/dl) 211.3 ± 63.6 188.1 ± 97.4 <0.0006
APO AI (mg/dl) 107.2 ± 17.5 129.1 ± 23.1 <0.0001
APO B (mg/dl) 117.7 ± 25.5 101.1 ± 24.9 <0.01
APO AII (mg/dl) 38.7 ± 6.4 43.9 ± 9.0 <0.001
APO CII (mg/dl) 4.03 ± 1.4 3.99 ± 1.6 NS
APO CIII (mg/dl) 12.1 ± 2.3 13.1 ± 3.2 <0.008
APO E (mg/dl) 8.6 ± 2.1 10.2 ± 3.3 <0.0001
Data are given as means ± SD. Smokers were those currently smoking at baseline. The statistical analysis of total triglycerides and Lp(a) were 
performed on log-transformed values, but the untransformed values are given in table. After age-standardisation, continuous variables were 
compared by t-test and ANOVA, and categorical variables by χ2 testBMC Medical Genetics 2003, 4 http://www.biomedcentral.com/1471-2350/4/8
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Genotypes in Arterial disease
Case-control analyses of genotype distributions and allele
frequencies between the two groups with or without arte-
rial disease showed significant differences only for the
apolipoprotein B Xba1 polymorphism, for the Apo E vari-
ants and for the T202T variant of the LPIC gene (Table 2).
All the other gene polymorphisms were not associated
with CAD in our population. Multivariate analysis of all
the six genes, accounting for clinical (age, sex, BMI) and
lipid parameters, showed that the ApoB Xba1 polymor-
phism and apolipoprotein E4 allele were independently
associated with arterial disease (p < 0.01, data not
shown).
Apolipoprotein, Lipoprotein lipase and LIPC genotypes 
and lipid levels
Associations with lipid parameters were analysed in those
genes that were associated with CAD in univariate analy-
sis,. In the CAD group, significant comparisons of lipid,
lipoprotein and apolipoprotein levels between alleles are
presented in Table 3. Plasma cholesterol (p = 0.03), LDL-
cholesterol (p = 0.005) and Apo B (p = 0.002) levels were
associated to Apo E variants. Also Apo E level were related
to the Apo E alleles. Alleles at the Apo B Xba1 polymor-
phisms associated with plasma HDL-cholesterol and Apo
B levels (p < 0.01).
Finally, lower HDL-cholesterol and higher triglycerides
levels were associated with the T202T variant of LPIC gene
(p = 0.01). (Table 3).
Evaluation of clinical outcomes of CAD and gene variants
In our CAD population we investigated from clinical
records and from interviews the occurrence of a second
cardiovascular event (a second coronary angioplasty
(PTCA), myocardial infarction, coronary artery by-pass
graft (CABG), cardiovascular deaths) in those who had a
PTCA at the time of recruitment (1993–94). Data on clin-
ical outcomes after 8 years were available for 60 subjects:
45 (72.5%) had a cardiovascular event, of which 22 had a
CABG and 23 underwent a second PTCA (6 within one
year); 4 of these 45 patients were reported dead. Because
of the relatively small size of this sample, we were unable
to analyse subsets of these patients, and considered the
second CAD event as evidence of the progression of the
atherosclerotic disease. Baseline characteristics of these
patients were not significantly different from the other
CAD patients (data not shown). When the occurrence of a
second cardiovascular event was related to genotypes, a
strong association was observed with the LIPC gene T202T
variant (p < 0.02). This association was confirmed by mul-
tiple logistic regression analysis, were a significant inde-
pendent association was demonstrated in the presence of
other known risk factors. (table 4)
Table 2: Frequencies of rare alleles in CAD and controls subjects at each gene locus
Allele frequencies
Gene polymorphism CAD subjects n = 102 Control subjects n = 104 p-value
Apo AI
Xmn1 0.154 0.228 NS
Msp1 0.081 0.094 NS
Pst1 0.091 0.094 NS
Apo B
Xba1 0.330 0.440 <0.03§
Apo CIII
C3175G 0.112 0.099 NS
Apo E
e2 0.080 0.026 P < 0.05#
e3 0.840 0.914
e4 0.080 0.060
LIPC
T202T (C to G) 0.362 0.526 <0.02¶
LPL
HindIII 0.280 0.278 NS
S447X (C to G) 0.112 0.133 NS
N291S (A to G) 0.012 0.017 NS
D9N (G to A) 0.031 0.011 NS
§ CAD subjects vs controls: allele frequencies χ2 = 5.02, df = 1, p < 0.03. # CAD subjects vs controls: allele frequencies χ2 = 7.02, df = 2, p < 0.05. ¶ 
CAD subjects vs controls: allele frequencies χ2 = 5.45, df = 1, p < 0.02.BMC Medical Genetics 2003, 4 http://www.biomedcentral.com/1471-2350/4/8
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Discussion
Italy ranks as one of the lowest in mortality rates for coro-
nary artery disease in Europe [8], yet many of the conven-
tional risk factors showed significant differences in our
patients with coronary artery disease compared to healthy
Italian controls. The frequency of smokers was higher in
the arterial disease group; and plasma LDL cholesterol,
triglycerides, and Lp(a) were also raised in the disease
group whereas HDL-cholesterol was reduced. Interest-
ingly total plasma cholesterol did not discriminate
between cases and controls as in other European countries
[17]. Multiple regression analysis confirmed the inde-
pendent predictive role for all of the above mentioned
lipid parameters.
Of the six lipid loci studied (for a total of 11 polymor-
phisms) the apolipoprotein E,  ApoB  and  LIPC  polymor-
phisms distinguished between case and controls in
univariate analysis. However, multivariate analysis
accounting for clinical and metabolic predictors of CAD
showed that only Apo E and ApoB Xba1 polymorphisms
were independently associated with CAD in this Italian
population. This latter result confirms previous associa-
tion studies where the allele possessing the XbaI site was
found to be associated with higher levels of total choles-
terol, LDL, apoB and triglycerides, and it was concluded
that this genotype confers increased risk of myocardial
infarction [5,20]. Also results on the Apo E gene associa-
tion confirm previous observations [9]. When lipid
parameters were related to genotypes, the ApoE, ApoB and,
LIPC gene polymorphisms were associated with various
markers of dyslipidaemia in this CAD population, con-
firming previous reports of the influence of these gene
polymorphisms on lipid parameters (reviewed in [7]).
The most interesting result in our study was the observa-
tion that the LIPC (hepatic lipase) gene T202T polymor-
phisms was independently associated with clinical
Table 3: Comparison of plasma lipids and apoproteins levels according to alleles in CAD subjects (n. 102)
Apo E Apo B Xba1 LIPC T202T
-/2 (14) 3/3 (74) -/4 (14) X1 (35) X2 (67) C carriers (39) G carriers (65)
Total cholesterol (mg/dl) 156 ± 20 199.29 204 ± 34* 191 ± 34 206 ± 35 199 ± 41 198 ± 33
HDL-cholesterol (mg/dl) 26.8.4 ± 5.2 25.9 ± 7.1 26.76 ± 6.7 29 ± 9.6 26 ± 2.0* 34 ± 10 31.7 ± 10*
LDL-cholesterol (mg/dl) 98 ± 24 134 ± 31 141 ± 11* 138 ± 35 149 ± 36 130 ± 34 133 ± 39
Total triglycerides (mg/dl) 189.7 ± 45 178.3 ± 101 178.3 ± 80 210 ± 57 212 ± 67 170 ± 83 203 ± 81*
APO AI (mg/dl) 108.3 ± 14 105.4 ± 15 106.0 ± 10 107 ± 17 106 ± 15 119 ± 23 117 ± 22
APO AII (mg/dl) 37 ± 5.2 38 ± 6.1 38 ± 9.2 38.7 ± 6.6 38.5 ± 6.3 41 ± 8.2 41 ± 6.1
APO B (mg/dl) 77 ± 16 110 ± 19 117 ± 21* 100 ± 30 112 ± 22¶ 104 ± 27 105 ± 23
APO CII (mg/dl) 4.4 ± 1.8 3.8 ± 1.6 3.7 ± 1.4 4.0 ± 1.3 3.9 ± 1.9 4.0 ± 1.6 3.9 ± 1.7
APO CIII (mg/dl) 11.6 ± 2.3 11.3 ± 2.6 12.7 ± 2.4 13.6 ± 2.1 12.3 ± 2.3 12.8 ± 2.8 12.4 ± 2.9
APO E (mg/dl) 11.0 ± 3.2 7.9 ± 1.7 8.7 ± 1.7¶ 9.4 ± 2.7 9.0 ± 2.6 9.4 ± 2.6 9.3 ± 3.1
Data are given as means ± SDM. Significant differences are in bold Apo E: -/2 = carriers of allele ε 2; 3/3 = homozygous carriers of allele ε 3; -/4 
carriers allele ε4. *p < 0.01, ¶ p < 0.03 Apo B: X1X1 v. X1X2 + X2X2. *p < 0.01 ¶ p < 0.05 LIPC (Hepatic lipase): C allele carriers (wild type) v. 
G allele carriers (CG + GG) * p < 0.02; † p < 0.01 The statistical analysis of total triglycerides and LP(a) were performed on log-transformed values, 
but the untransformed values are given in table. After age-standardisation, continuous variables were compared by t-test and ANOVA, and 
categorical variables by χ2 test
Table 4: Relative risk of clinical outcomes (a second PTCA, myocardial infarction, CABG, cardiovascular death) according to LIPC gene 
genotypes
LIPC status CAD subjects with clinical 
outcomes
CAD subjects without clinical 
outcomes
n. (%) n. (%) Odds ratio (95% CI)
CC (wild type) carriers 6 (13.4%) 9 (60%) 1
GG + GC carriers 39 (86.6%) 6 (40%) 7.6 (1.01–57.2)*
Odds ratios were adjusted for age, sex, plasma triglycerides, LDL-cholesterol, HDL-cholesterol, smoking habits (yes/no). Triglycerides were also 
independent predictors of clinical outcomes (OR 1.01 (95% CI: 1.00–1.02), p < 0.04) * p < 0.03BMC Medical Genetics 2003, 4 http://www.biomedcentral.com/1471-2350/4/8
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outcomes in patients with established CAD. Thus, when
the occurrence of a second cardiovascular event was
related to genotypes, a strong association by multiple
logistic regression analysis was observed with the LIPC
gene T202T variant. Also this variant was associated with
reduced HDL-cholesterol levels in our population. Low
hepatic lipase activity has been shown to be associated
with an increased risk for CAD [21]. Hepatic lipase is a
lipolytic enzyme synthesised in liver cells, and has a dual
role in lipid metabolism. It is involved in chylomicron
remnant catabolism and in HDL metabolism, influencing
hepatic HDL interconversion [22] from large, cholesterol
ester-rich HDL particles to smaller particles that are ready
to accept cholesterol from cell membranes. Furthermore,
LDL buoyancy and size appear to be inversely associated
with hepatic lipase activity levels [23], and hepatic lipase
appears to influence LDL lipid composition by affecting
the surface lipid components.
Studies on hepatic lipase enzyme activity show that
hepatic lipase deficiency in most cases leads to triglyceride
enrichment in LDL and HDL lipoprotein fractions, pres-
ence of circulating β-VLDL and abnormal chylomicron
catabolism [24].
A role for the LIPC gene in atherosclerosis and CAD has
been proposed by genetic and functional studies [25,26].
Guerra et al. [25] examined the relationship between pol-
ymorphism in the gene coding for hepatic lipase, using a
sequential approach comprising linkage analysis, DNA
sequencing and association studies. This study concluded
that allelic variation at, or closely linked to, the LIPC gene
accounts for about 25% of the plasma HDL-cholesterol
variation in concentrations. Moennig et al. [26]
sequenced the LIPC gene in patients with low HDL/high
triglycerides and CAD, and their results suggested that
mutations in LIPC may play a role in the pathogenesis of
atherosclerosis. The polymorphism that we have studied
(T202T) has been shown to be in linkage disequilibrium
with other LIPC  gene polymorphisms: L334F,  T457T
(linkage disequilibrium coefficients were -1.00 and -0.96,
respectively) and weakly to-C480T [27], also described as
C-514T. This latter polymorphism was reported associ-
ated with a lower hepatic lipase activity in CAD patients
[28]. This observation has been subsequently confirmed
[29], suggesting that the common LIPC promoter variant-
C480T  is functional and associated with an impaired
hepatic lipase activity influencing lipoproteins metabo-
lism. Furthermore, hepatic lipase enzyme with the L334F
variant was shown in in vitro expression studies to have
only about 30% of the enzymatic activity of the wild-type
enzyme [30]. It is thus possible that the T202T variant,
which is one of the more common polymorphisms of
LIPC gene, is a simple marker of one of the other LIPC var-
iants, considering also that it is in linkage disequilibrium
with these other polymorphisms and in particular with
the L334F variant. We acknowledge that our sample was
small, and these results should be considered preliminary,
although an 8 years follow up is long enough to deter-
mine clinical outcomes. Moreover, several reports have
demonstrated an important role for the LIPC gene in the
risk of CAD and its related lipid abnormalities. Low HDL-
cholesterol and LDL subclass distribution, both influ-
enced by hepatic lipase activity, have been shown to be
strong risk factors for early atherosclerosis [23,31]. Thus,
further studies on sequence variations of the LIPC gene in
CAD patients are warranted, in particular looking at the
possible influences on clinical outcomes. The possibility
to predict by genetic analysis the risk of progression of cor-
onary atherosclerotic lesions would be of great impor-
tance for the management of CAD patients.
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